Inhibition of renin-angiotensin system: Implications for diabetes control and prevention

Journal of Investigative Medicine

Volumn 61, Issue 3, 2013, Pages 551-557

  Prabhakar, Sharma S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin inhibitors; Diabetes prevention; Insulin signaling

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NEW ONSET DIABETES MELLITUS; NONHUMAN; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANGIOTENSINS; ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN; INSULIN RESISTANCE; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84877885974     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31828298ce     Document Type: Conference Paper

References (43)

1. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119:S10-S16.
2. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev. 2012;13:136-149.
3. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci. 2011;32(12):734-739.
4. Muscogiuri G, Chavez AO, Gastaldelli A, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol. 2008;6:301-312.
5. Zhou MS, Schulman IH, Zeng Q. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med. 2012;17(5):330-334.
6. Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am. 2009;93(3):569-582.
7. Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin- aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012;14:160-169.
8. Marrero MB, Fulton D, Stepp D, et al. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol. 2004;24:2009-2013.
9. Mathai ML, Chen N, Cornall L, et al. The role of angiotensin in obesity and metabolic disease. Endocr Metab Immune Disord Drug Targets. 2011;11(3):198-205.
10. Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219-H1230.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160): 713-720.
12. The Captopril Prevention Project (CAPP) Study Group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Curr Hypertens Rep. 1999;1(6):466-467.
13. The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin converting enzyme inhibitor on the cardiovascular events in high risk patients. N Engl J Med. 2000;342:145-153.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
15. Lindholm LH, Ibsen H, Borch-Johnsen K, et al; LIFE study group. Risk of new onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertension. 2002;20:1879-1886.
16. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771.
17. Kjeldsen SE, Julius S, Mancia G, et al; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24(7):1405-1412.
18. Poulter NR, Wedel H, Dahlöf B, et al; ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005; 366(9489):907-913.
19. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. A meta-analysis of randomized clinical trials. Diabetes Metab. 2004;30(6):487-496.
20. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23(3):463-473.
21. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358(15):1547-1559.
22. Barzilay JI, Gao P, Rydén L, et al; TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011;34(9):1902-1907.
23. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16): 1477-1490.
24. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321(13):868-873.
25. Velasquez MT, Bhathena SJ, Striffler JS, et al. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism. 1998;47(12 suppl 1):7-11.
26. Suzuki H, Motley ED, Frank GD, et al. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:305-322.
27. Azekoshi Y, Yasu T, Watanabe S, et al. Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells. Hypertension. 2010;56(1):136-142.
28. Graciano MF, Valle MM, Kowluru A, et al. Regulation of insulin secretion and reactive oxygen species production by free fatty acids in pancreatic islets. Islets. 2011;3(5):213-223.
29. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011;51(5):993-999.
30. Han SH, Sakuma I, Shin EK, et al. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis. 2009;52(2):126-140.
31. Vaidya A, Forman JP, Underwood PC, et al. The influence of body mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men. Eur J Endocrinol. 2011;164(6):995-1002.
32. Vaidya A, Williams JS. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism. 2012;61(4):450-458.
33. Rafiq K, Nagai Y, Nakano D. Prorenin/renin and insulin resistance. Front Biosci (Elite Ed). 2010;1(2):1143-1146.
34. Flynn C, Bakris GL. Interaction between adiponectin and aldosterone. Cardiorenal Med. 2011;1(2):96-101.
35. Calegari VC, Alves M, Picardi PK, et al. Suppressor of cytokine signaling-3 provides a novel interface in the crosstalk between angiotensin II and insulin signaling systems. Endocrinology. 2005; 146(2):579-588.
36. Yu W, Chen C, Fu Y, et al. Insulin signaling: a possible pathogenesis of cardiac hypertrophy. Cardiovasc Ther. 2010;28(2):101-105.
37. Johansson ME, Andersson IJ, Alexanderson C, et al. Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2008;294(4):R1240-R1247.
38. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 2002;40:872-879.
39. Taniyama Y, Hitomi H, Shah A, et al. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol. 2005;25:1142-1147.
40. Prabhakar S, Starnes J, Shi S, et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol. 2007;18(11):2945-2952.
41. Rao RH. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens. 1994;7:655-660.
42. Hus-Citharel A, Bouby N, Iturrioz X, et al. Multiple cross talk between angiotensin II, bradykinin, and insulin signaling in the cortical thick ascending limb of rat kidney. Endocrinology. 2010;151(7):3181-3194.
43. Swislocki AL, Siegel D, Jialal I. Pharmacotherapy for the metabolic syndrome. Curr Vasc Pharmacol. 2012;10(2):187-205.